What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.
Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several year...
Hlavní autoři: | Testa, L, Bhindi, R, Van Gaal, W, Latini, R, Pizzocri, S, Lanotte, S, Biondi Zoccai, G, Valgimigli, M, Laudisa, M, Brambilla, N, Banning, A, Bedogni, F |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
2010
|
Podobné jednotky
-
Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis.
Autor: Testa, L, a další
Vydáno: (2010) -
Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents
Autor: L. Testa, a další
Vydáno: (2010-01-01) -
Use of prasugrel in patients with clopidogrel hypersensitivity
Autor: Aparna Joshi, a další
Vydáno: (2022-01-01) -
Interaction between statins and clopidogrel: is there anything clinically relevant?
Autor: Bhindi, R, a další
Vydáno: (2008) -
Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition.
Autor: Testa, L, a další
Vydáno: (2009)